Aquestive Therapeutics Total Assets Growth & History (AQST)
Aquestive Therapeutics's total assets was $160.4M for fiscal 2025.
View full Aquestive Therapeutics company overviewAquestive Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $160.4M | $59.0M | +58.17% |
| 2024 | 2024-12-31 | $101.4M | $44.0M | +76.64% |
| 2023 | 2023-12-31 | $57.4M | $348,000 | +0.61% |
| 2022 | 2022-12-31 | $57.1M | −$4.9M | −7.94% |
| 2021 | 2021-12-31 | $62.0M | −$891,000 | −1.42% |
| 2020 | 2020-12-31 | $62.9M | −$15.6M | −19.87% |
| 2019 | 2019-12-31 | $78.5M | −$8.4M | −9.64% |
| 2018 | 2018-12-31 | $86.9M | $43.7M | +101.44% |
| 2017 | 2017-12-31 | $43.1M | — | — |
Aquestive Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $132.1M | $38.4M | +40.99% |
| Q1 2026 | 2026-03-31 | $141.1M | $38.9M | +38.04% |
| Q4 2025 | 2025-12-31 | $160.4M | $59.0M | +58.17% |
| Q3 2025 | 2025-09-30 | $163.6M | $53.6M | +48.75% |
| Q2 2025 | 2025-06-30 | $93.7M | −$23.9M | −20.33% |
| Q1 2025 | 2025-03-31 | $102.2M | −$27.3M | −21.07% |
| Q4 2024 | 2024-12-31 | $101.4M | $44.0M | +76.64% |
| Q3 2024 | 2024-09-30 | $110.0M | $50.5M | +84.97% |
| Q2 2024 | 2024-06-30 | $117.6M | $60.6M | +106.35% |
| Q1 2024 | 2024-03-31 | $129.5M | $68.2M | +111.35% |
| Q4 2023 | 2023-12-31 | $57.4M | $348,000 | +0.61% |
| Q3 2023 | 2023-09-30 | $59.4M | $7.6M | +14.66% |
| Q2 2023 | 2023-06-30 | $57.0M | $684,000 | +1.21% |
| Q1 2023 | 2023-03-31 | $61.3M | $4.8M | +8.41% |
| Q4 2022 | 2022-12-31 | $57.1M | −$4.9M | −7.94% |
| Q3 2022 | 2022-09-30 | $51.8M | −$13.4M | −20.60% |
| Q2 2022 | 2022-06-30 | $56.3M | −$10.6M | −15.80% |
| Q1 2022 | 2022-03-31 | $56.5M | −$5.4M | −8.71% |
| Q4 2021 | 2021-12-31 | $62.0M | −$891,000 | −1.42% |
| Q3 2021 | 2021-09-30 | $65.3M | $14.9M | +29.49% |
| Q2 2021 | 2021-06-30 | $66.9M | $3.3M | +5.24% |
| Q1 2021 | 2021-03-31 | $61.9M | −$2.6M | −3.98% |
| Q4 2020 | 2020-12-31 | $62.9M | −$15.6M | −19.87% |
| Q3 2020 | 2020-09-30 | $50.4M | $1.6M | +3.29% |
| Q2 2020 | 2020-06-30 | $63.5M | $13.1M | +26.06% |
| Q1 2020 | 2020-03-31 | $64.5M | −$3.5M | −5.14% |
| Q4 2019 | 2019-12-31 | $78.5M | −$8.4M | −9.64% |
| Q3 2019 | 2019-09-30 | $48.8M | −$41.2M | −45.76% |
| Q2 2019 | 2019-06-30 | $50.4M | $10.6M | +26.52% |
| Q1 2019 | 2019-03-31 | $68.0M | — | — |
| Q4 2018 | 2018-12-31 | $86.9M | $43.7M | +101.44% |
| Q3 2018 | 2018-09-30 | $90.0M | — | — |
| Q2 2018 | 2018-06-30 | $39.8M | — | — |
| Q4 2017 | 2017-12-31 | $43.1M | — | — |
Aquestive Therapeutics total assets trends
Over the last five fiscal years, Aquestive Therapeutics's total assets increased from $62.9M to $160.4M, a change of $97.5M. The latest reported quarter, Q2 2026, shows $132.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aquestive Therapeutics source filings ↗